Author: Ravi Shankar

ATLANTA, Sept. 28, 2026 (GLOBE NEWSWIRE) — Gray Media, Inc. (“Gray”) (NYSE: GTN) today announced updated financial guidance for the quarter ending September 30, 2026, updating guidance originally issued on August 7, 2026. The update is being provided in connection with lender meetings to potentially refinance its credit facility and presentations to investors it may make from time to time. While Gray is in the process of finalizing its third quarter financial results, the following updated estimates reflect the most current operational information and expectations available to the company as of the date of this release. For the estimates not listed below, our original guidance issued on August 7, 2026, remains unchanged. As always, guidance may change in the future based on several factors and therefore may not reflect future actual results.

	Quarter Ending September 30, 2026
	September 30, 2025				August 7, 2026			September 28, 2026
(in millions)	(Unaudited)				GUIDANCE			UPDATE
Revenue (less agency commissions):
Core advertising	$	355			Flat, as reported			-1% to Flat, as reported
Political advertising	$	8			$165 – $185			$188 – $195
Total revenue	$	749			$935 – $965			$950 – $965
Operating expenses (excluding depreciation, amortization and (gain) loss on disposal of assets):
Total corporate and administrative expense	$	28			$35 – $40			$30 – $35

For illustrative purposes, the table below highlights political advertising revenue trends for the first nine months of this year alongside the first nine months of the two prior “on-year” political cycles. The 2026 estimate assumes $192 million of third quarter political advertising revenue, the midpoint of Gray’s updated guidance, and includes an estimated $9 million of political advertising revenue from recent acquisitions through September 30, 2026, which is included in the updated guidance.

Gray currently anticipates that it will have no outstanding borrowings under its Revolving Credit Facility as of September 30, 2026. Current borrowing capacity under Gray’s Accounts Receivable Securitization facility is approximately $379 million, reflecting lower core commercial receivables driven by strong political advertising revenues, which are paid in advance.

Gray currently expects to report its third quarter 2026 financial results on Friday, November 6, 2026, and host its quarterly investor call at 11AM that morning.

The Company

We are a multimedia company headquartered in Atlanta, Georgia. We are the nation’s largest owner of top-rated local television stations and digital assets. We serve 117 full-power television markets that collectively reach approximately 37% of US television households. The portfolio includes 78 markets with the top-rated television station and 101 markets with the first and/or second highest rated television station in average all-day ratings across the 116 of such markets that were measured by Nielsen in 2025. We also own the largest Telemundo Affiliate group with 46 markets and Gray Digital Media, a full-service digital agency offering national and local clients digital marketing strategies with the most advanced digital products and services. Our additional media properties include video production companies Raycom Sports, Tupelo Media Group, and PowerNation Studios, and studio production facilities Assembly Atlanta and Third Rail Studios..

Cautionary Statements for Purposes of the “Safe Harbor” Provisions of the Private Securities Litigation Reform Act

This press release contains certain forward-looking statements that are based largely on our current expectations and reflect various estimates and assumptions by us. These statements are statements other than those of historical fact and may be identified by words such as “estimates,” “expect,” “anticipate,” “will,” “implied,” “assume” and similar expressions. Forward-looking statements are subject to certain risks, trends and uncertainties that could cause actual results and achievements to differ materially from those expressed in such forward-looking statements. Such risks, trends and uncertainties, which in some instances are beyond our control, include: the inability to achieve estimates of future revenue and expenses, and other future events. We are subject to additional risks and uncertainties described in our quarterly and annual reports filed with the Securities and Exchange Commission from time to time, including in the “Risk Factors,” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections contained therein, which reports are made publicly available via our website, www.graymedia.com. Any forward-looking statements in this press release should be evaluated in light of these important risk factors. This press release reflects management’s views as of the date hereof. Except to the extent required by applicable law, Gray undertakes no obligation to update or revise any information contained in this press release beyond the published date, whether as a result of new information, future events or otherwise. Information about certain potential factors that could affect our business and financial results and cause actual results to differ materially from those expressed or implied in any forward-looking statements are included under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in our Annual Report on Form 10-K for the year ended December 31, 2025, and may be contained in reports subsequently filed with the U.S. Securities and Exchange Commission and available at www.sec.gov.

Gray Contact:

Alan Gould, Vice President, Investor Relations, (404) 266-8333, alan.gould@graymedia.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a1dc3a45-4556-47c7-bf01-ac642ca5af5f

   Heineken Holding N.V. reports transactions under its current

share buyback programme

Amsterdam 28 September 2026 – Heineken Holding N.V. (EURONEXT:HEIO; OTCQX: HKHHY), hereby reports transaction details related to the second tranche of up to circa €375 million tranche of its share buyback programme of up to circa €750 million as communicated on 12 February 2026.

From 21 September 2026 up to and including 25 September 2026 a total of 164,949 shares were repurchased on exchange at an average price of €66.84.

Up to and including 25 September 2026, a total of 3,907,657 shares were repurchased under the second tranche of the share buyback programme for a total consideration of €256,515,756.

Heineken Holding N.V. publishes on a weekly basis, every Monday, an overview of the progress of the share buyback programme on its website: https://www.heinekenholding.com/investors/share-information/share-buyback-programm

Enquiries

Media Heineken Holding N.V.
Kees Jongsma
tel. +31 6 54 79 82 53
E-mail: cjongsma@spj.nl
Media		Investors
Christiaan Prins		Tristan van Strien
Director of Global Communications		Global Director of Investor Relations
Marlie Paauw		Lennart Scholtus / Chris Steyn
Global Media Lead		Investor Relations Manager / Senior Analyst
E-mail: pressoffice@heineken.com		E-mail: investors@heineken.com
Tel: +31-20-5239355		Tel: +31-20-5239590

Regulatory information:

This press release is issued in connection with the disclosure and reporting obligations as set out in Article 5(1)(b) Regulation (EU) 596/2014 and Article 2(2) of the Commission Delegated Regulation (EU) 2016/1052 that contains technical standards for buyback programs.

Editorial information:
Heineken Holding N.V. engages in no activities other than its participating interest in Heineken N.V. and the management or supervision of and provision of services to that company. HEINEKEN is the world’s pioneering beer company. It is the leading developer and marketer of premium and non-alcoholic beer and cider brands. Led by the Heineken® brand, the Group has a portfolio of more than 340 international, regional, local and specialty beers and ciders. With HEINEKEN’s over 85,000 employees, HEINEKEN brews the joy of true togetherness to inspire a better world. HEINEKEN’s dream is to shape the future of beer and beyond to win the hearts of consumers. HEINEKEN is committed to innovation, long-term brand investment, disciplined sales execution and focused cost management. Through “Brew a Better World”, sustainability is embedded in the business. HEINEKEN has a well-balanced geographic footprint with leadership positions in both developed and developing markets. HEINEKEN operates breweries, malteries, cider plants and other production facilities in more than 70 countries. Most recent information is available on www.heinekenholding.com and www.theheinekencompany.com and follow HEINEKEN on LinkedIn and Instagram.

Attachment

• 20260928 HHNV SBB Weekly update 21 September 2026 – 25 September 2026

FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY
Rule 8.5 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)        Name of exempt principal trader:	Investec Bank Plc
(b)        Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree	SThree Plc
(c)        Name of the party to the offer with which exempt principal trader is connected:	Investec is Joint Broker to SThree Plc
(d)        Date dealing undertaken:	25th September 2026
(e)        In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?         If it is a cash offer or possible cash offer, state “N/A”	N/A

2.        DEALINGS BY THE EXEMPT PRINCIPAL TRADER

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security	Purchases/ sales	Total number of securities	Highest price per unit paid/received	Lowest price per unit paid/received
Ordinary shares	Purchases	27,396	304.75	302
Ordinary shares	Sales	27,560	304.75	302

(b)        Cash-settled derivative transactions

Class of relevant security	Product description e.g. CFD	Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position	Number of reference securities	Price per unit
N/A	N/A	N/A	N/A	N/A

(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security	Product description e.g. call option	Writing, purchasing, selling, varying etc.	Number of securities to which option relates	Exercise price per unit	Type e.g. American, European etc.	Expiry date	Option money paid/ received per unit
N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

(ii)        Exercise

Class of relevant security	Product description e.g. call option	Exercising/ exercised against	Number of securities	Exercise price per unit
N/A	N/A	N/A	N/A	N/A

(d)        Other dealings (including subscribing for new securities)

Class of relevant security	Nature of dealing e.g. subscription, conversion	Details	Price per unit (if applicable)
N/A	N/A	N/A	N/A

3.        OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i)        the voting rights of any relevant securities under any option; or (ii)        the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none”

None

Date of disclosure:	28th September 2026
Contact name:	Abhishek Gawde
Telephone number:	+91-9923757332

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at ssssssswwww.thetakeoverpanel.org.uk.

HOUSTON, Sept. 28, 2026 (GLOBE NEWSWIRE) — KBR (NYSE: KBR) today announced that KBR and Trinzic, the planned spin-off of KBR’s Mission Technology Solutions business, will host separate Investor Day events in New York City. KBR Investor Day will be held on November 11, 2026, and Trinzic Investor Day will be held on November 12, 2026, providing investors with the opportunity to hear directly from the leadership teams of each future standalone company.

At KBR’s Investor Day, members of the executive leadership team will discuss the company’s strategy, growth outlook, financial framework and capital allocation priorities as a focused standalone company following the planned separation.

At Trinzic’s Investor Day, the future executive leadership team will provide an overview of the company’s strategic vision, differentiated market position, long-term growth opportunities and financial outlook as an independent public company.

A live webcast and presentation materials for both events will be available on the day of each event. Due to limited capacity, in-person attendance is by invitation only. Interested individuals may register for the KBR webcast here and the Trinzic webcast here. Replays will be available at investors.kbr.com following the conclusion of each event.

About KBR

KBR is a global, capital-light lifecycle solutions company serving customers in high-complexity industrial, energy and infrastructure markets. Through its advisory, technical, engineering and operating expertise, KBR helps customers shape investments, reduce risk, deploy complex technologies, improve performance and deliver reliable outcomes across the asset lifecycle.

Following the planned separation of the Mission Technology Solutions business, KBR will operate as a focused standalone company with differentiated customer relationships, global execution capabilities and a capital-efficient business model. The company is positioned to benefit from long-term secular growth trends across energy security, energy transition, industrial modernization, and infrastructure investment. KBR’s 15,000 employees operate across more than 40 countries.

About Trinzic

KBR’s Mission Technology Solutions business is expected to be spun off as an independent public company in January 2027 and will then operate under the new name Trinzic. The name is inspired by the word intrinsic, reflecting the essential capabilities, deep expertise, speed and trusted performance that have defined the business for decades. Trinzic will enter the market as a global company and partner to customers supporting some of the highest priority missions across national security, human performance, global operations and space. Trinzic will launch with more than $5 billion in annual revenue, established partnerships and contracts, 18,000 employees and a global footprint.    

Forward Looking Statements

The statements in this press release that are not historical statements, including statements regarding future financial performance, are forward-looking statements within the meaning of the federal securities laws. These statements are subject to numerous risks, uncertainties and assumptions, many of which are beyond the company’s control, that could cause actual results to differ materially from the results expressed or implied by the statements. These risks, uncertainties and assumptions include, but are not limited to, those set forth in the company’s most recently filed Annual Report on Form 10-K, any subsequent Form 10-Qs and 8-Ks and other U.S. Securities and Exchange Commission filings, which discuss some of the important risks, uncertainties and assumptions that the company has identified that may affect its business, results of operations and financial condition. Due to such risks, uncertainties and assumptions, you are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. Except as required by law, the company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

For further information, please contact:

Investors
Rachael Goldwait
Vice President, Investor Relations
713-753-5082
Investors@kbr.com

Media
Philip Ivy
Vice President, Global Communications and Marketing
713-753-3800
MediaRelations@kbr.com

Amendment to Trafigura agreement provides Project with the option to deliver up to an additional 4,000 metric tonnes of battery-quality lithium carbonate per year, on top of the initial 8,000 metric tonne per year commitment

All figures are in US dollars unless otherwise stated.

LEWISVILLE, Ark., Sept. 28, 2026 (GLOBE NEWSWIRE) — Smackover Lithium, a partnership between Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (NYSE.A: SLI) (TSXV: SLI), through its subsidiaries, and Equinor, through subsidiaries of Equinor ASA, today announced that it has amended its binding commercial offtake agreement (the “Agreement”) with Trafigura Trading LLC (“Trafigura”) for the South West Arkansas Project (“SWA Project” or the “Project”). The amendment provides the additional offtake volumes targeted to complete the Project’s customer offtake process and move to finalize the ongoing debt financing process.

Trafigura is a market leader in the global commodities industry, with an established presence across battery metal markets, including lithium. As one of the largest commodity traders in the world, Trafigura provides valuable access to multiple industry supply chains that rely on lithium chemicals along with a broad suite of customers.

Under the amended terms of the Agreement, Smackover Lithium now has the option, at its own election, to supply Trafigura with up to an additional 4,000 metric tonnes of battery-quality lithium carbonate in each year of the 10-year Agreement beginning at the start of commercial production. Combined with the initial 8,000 metric tonnes per year commitment under the Agreement, the maximum possible volumes to be delivered to Trafigura on a take-or-pay basis has increased to 12,000 metric tonnes of battery-quality lithium carbonate per year. Pricing and other key commercial terms remain subject to confidentiality.

The amended Agreement also provides valuable production flexibility for the Project. Because the additional volume is deliverable solely at Smackover Lithium’s election, it retains the ability to allocate that volume to other strategic customers in the future if a superior commercial or strategic opportunity emerges. Importantly, an additional offtake agreement is not required to move forward with the Project financing process.

The target for the SWA Project was to secure customer offtake agreements for roughly 80% (18,000) of the 22,500 tonnes of annual nameplate lithium carbonate capacity in its initial phase. Together with the recently announced binding take-or-pay agreement with LG Energy Solution for 8,000 metric tonnes per year, total possible commitments have now reached 20,000 metric tonnes of battery-quality lithium carbonate per year, exceeding the initial target.

Smackover Lithium now has sufficient offtake commitments to focus on finalizing its Project debt financing efforts. Due diligence and other customary processes in furtherance of Project financing are well underway with three major Export Credit Agencies. The Project continues to target a senior secured, limited recourse debt financing package of around $1.1 billion as outlined in its financing update on December 9, 2025.

David Park, Chief Executive Officer of Standard Lithium, stated, “This is a pivotal milestone for the SWA Project and a testament to the strength of our customer relationships. The offtake process has been one of the most important and time-intensive workstreams and we now have the volume commitments needed to support our Project debt financing, as well as the flexibility to continue to pursue transactions that maximize value for our stakeholders. Our path forward is clear as we focus on finalizing and closing the Project financing, taking FID and beginning construction.”

Having successfully completed the commercial offtake workstream, Smackover Lithium continues to target a Final Investment Decision (FID) on the SWA Project later this year before moving promptly into construction. This would enable first commercial production of battery-quality lithium carbonate in 2029.

Qualified Person

All scientific and technical disclosure in this news release was reviewed and approved by Mr. Stephen Ross, P.Geo., British Columbia, Vice President of Resource Development for Standard Lithium and a Qualified Person for purposes of, and as that term is defined in, National Instrument 43-101 – Standards of Disclosure for Mineral Projects. Mr. Ross is not independent of the Company.

Department of Energy Acknowledgement and Disclaimer

This material is based upon work supported by the U.S. Department of Energy’s Office of Critical Minerals and Energy Innovation under award Number DE-MS0000099. The views expressed herein do not necessarily represent the views of the U.S. Department of Energy or the United States Government.

About Smackover Lithium

Smackover Lithium is a partnership between Standard Lithium and Equinor, through subsidiaries of Equinor ASA. Formed in May 2024, Smackover Lithium is developing multiple direct lithium extraction (“DLE”) projects in Southwest Arkansas and East Texas. Standard Lithium is the majority partner with a 55% interest and is the developer and operator of the projects. Equinor holds the remaining 45% interest in the projects.

About Standard Lithium Ltd.

Standard Lithium is a leading near-commercial lithium development company focused on the sustainable development of a portfolio of large, high-grade lithium-brine properties in the United States. The Company prioritizes industry leading projects characterized by large high-grade resources, robust infrastructure, skilled labor, and streamlined permitting. Standard Lithium aims to achieve sustainable, commercial-scale lithium production via the application of a scalable and fully integrated DLE and purification process. The Company’s flagship projects are in the Smackover Formation, an attractive lithium brine asset, focused in Arkansas and Texas. Standard Lithium is advancing the SWA Project, a greenfield project located in southern Arkansas, and a promising lithium brine resource position in East Texas, including the highest known lithium brine grade project in North America, the Franklin project.

Standard Lithium trades on both the TSX Venture Exchange (“TSXV”) and the NYSE American under the symbol “SLI”. Visit the Company’s website at www.standardlithium.com for more information.

About Equinor

Equinor is an international energy company committed to long-term value creation in a low-carbon future. Equinor’s portfolio of projects encompasses oil and gas, renewables, and low-carbon solutions, with an ambition of becoming a net-zero energy company by 2050. Headquartered in Norway, Equinor is the leading operator on the Norwegian continental shelf and has offices in more than 20 countries worldwide. Equinor’s partnership with Standard Lithium to mature DLE projects builds on its broad US energy portfolio of oil and gas, offshore wind, low carbon solutions, and battery storage projects.

For more information on Equinor in the U.S., please visit: Equinor in the US – Equinor.

About Trafigura

Trafigura provides critical resources to the world. Founded over 30 years ago and owned by its employees, the Group is at the heart of global supply, using its deep understanding of commodity markets to make supply chains more efficient, secure and sustainable.

Working across a global network, the Group deploys infrastructure, logistics, financing and market expertise to move energy and commodities from where they are produced to where they are needed. By connecting producers and consumers, we bring resilience and trust to complex supply chains. The business supplies the energy and commodities the world needs today, including oil and petroleum products, metals and minerals, gas and power, while investing in lower-carbon solutions for the future.

The Trafigura Group also comprises industrial assets and operating businesses including multi-metals producer Nyrstar, fuel storage and distribution company Puma Energy, fuel supplier and distributor Greenergy, and the Impala Terminals joint venture. The Group employs approximately 14,500 people, of which more than 1,400 are shareholders, and operates in over 150 countries.

Visit: www.trafigura.com

Investor Inquiries
Daniel Rosen
+1 604 409 8154
investors@standardlithium.com

Media Inquiries

media@standardlithium.com

Neither the TSXV nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

This news release may contain certain “Forward-Looking Statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws. When used in this news release, the words “anticipate”, “believe”, “estimate”, “expect”, “target”, “plan”, “forecast”, “may”, “could”, “should”, “schedule”, “predict”, “budget”, “project”, “potential” and other similar words or expressions identify forward-looking statements or information. These forward-looking statements or information may relate to the timing of any development of the SWA Project, the Agreement’s ability to move the Project towards FID and commercial production on the timelines anticipated, the expectation that the Project will provide Trafigura with a long-term, reliable supply of U.S. based and sustainably-produced battery-quality lithium carbonate, the amended Agreement’s ability to provide ongoing production flexibility, the anticipated pricing and take-or-pay structure of any additional offtake agreement, the ability of the Project to supply up to 12,000 metric tonnes per year of battery-quality lithium carbonate to Trafigura and up to 20,000 metric tonnes to all its offtake customers, generally, the ability to secure debt financing on terms and timelines acceptable to the Company, including the ability to obtain a debt financing package in the range of $1.1 billion, regulatory or government requirements or approvals and other factors or information. Such statements represent the Company’s current views with respect to future events and are necessarily based upon a number of assumptions and estimates that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political and social risks, contingencies and uncertainties. Many factors, both known and unknown, could cause results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements. The Company does not intend, and does not assume any obligation, to update these forward-looking statements or information to reflect changes in assumptions or changes in circumstances or any other events affecting such statements and information other than as required by applicable laws, rules and regulations.

Record-setting brow moment highlights the expertise behind Shoppers Drug Mart Beauty Services and its personalized approach

TORONTO, Sept. 28, 2026 (GLOBE NEWSWIRE) — Shoppers Drug Mart set a new Guinness World Records title at the 2026 Shoppers Drug Mart National Beauty Conference, with 673 Beauty Managers from across Canada participating in the record for the most people filling in their brows simultaneously.

Before the official attempt, Beauty Managers took part in a live brow mapping lesson led by Seneca Polytechnic professor, Derek Selby. Following the lesson, participants put their knowledge into practice using Quo Beauty® Microblade Brow Pen and Quo Beauty® Brow Defining Gel to fill in their brows, earning the new record. Brow mapping was chosen as the record-setting moment to highlight one of the personalized Beauty Services now available at select Shoppers Drug Mart locations.

The annual Shoppers Drug Mart National Beauty Conference brings together Shoppers Beauty Managers from across the country, helping them stay at the forefront of beauty innovation, trends and products, and further develop skills they bring to customers in-store. Beauty Managers have the opportunity to learn directly from brand experts and founders who share industry insights and their in-depth product knowledge.

“Our Beauty teams are at the heart of how we serve our customers,” said Derrick Pittman, Senior Vice-President, National Operations, Shoppers Drug Mart. “Their expertise and personalized advice, combined with our breadth of products and growing Beauty Services offering, help customers find what works best for them. We’re continuing to invest in our people and evolve our services, while delivering the choice, value and convenience customers expect from Shoppers Drug Mart.”

Beauty Services are expanding across Shoppers Drug Mart, with additional locations planned across the country in the coming months. Currently available in select locations across the Greater Toronto Area and British Columbia, customers can book personalized services, with the full service fee redeemable toward eligible beauty product purchases.

As Shoppers Drug Mart continues to evolve its Beauty Services offering, it is also investing in the expertise of its Beauty Specialists. This includes working with Seneca Polytechnic on makeup artistry training, with a pilot program set to begin before end of year. Through certified college instruction, the program builds Beauty Specialists’ makeup artistry skills and expertise to deliver a high-quality, personalized beauty experience that instills customer confidence.

Together, these investments combine expert advice, personalized services and an expanded assortment to deliver stronger value and more reasons for customers to shop at Shoppers Drug Mart, all while creating a more compelling, convenient and differentiated beauty experience.

About Shoppers Drug Mart Inc. 
Shoppers Drug Mart Inc. is one of the most recognized and trusted names in Canadian retailing. The company is the licensor of full-service retail drug stores operating under the name Shoppers Drug Mart® (Pharmaprix® in Québec). With more than 1,350 Shoppers Drug Mart® and Pharmaprix® stores operating in prime locations in each province and two territories, the company is one of the most convenient retailers in Canada. The company also licenses or owns more than 150 medical clinic pharmacies operating under the name Shoppers Simply Pharmacy® (Pharmaprix Simplement Santé® in Québec). In addition to its retail store network, the company owns Shoppers Drug Mart Specialty Health Network Inc., a provider of specialty drug distribution, pharmacy and comprehensive patient support services, MediSystem Inc., a provider of pharmaceutical products and services to long-term care facilities and Lifemark Health Group, Canada’s leading provider of outpatient physiotherapy, massage therapy, occupational therapy, chiropractic, mental health, and other ancillary rehabilitation services. Shoppers Drug Mart® is an independent operating division of Loblaw Companies Limited. 

For all media inquiries, contact: prloblaw@loblaw.ca 

Photos accompanying this announcement are available at: 

https://www.globenewswire.com/NewsRoom/AttachmentNg/a7eef452-88f4-4fb9-8f30-ba9e7c85d1bb

https://www.globenewswire.com/NewsRoom/AttachmentNg/33084ca9-be35-4574-afea-4c81d9ee88bb

Heineken N.V. reports the progress of transactions under its current
share buyback programme

Amsterdam, 28 September 2026 – Heineken N.V. (EURONEXT: HEIA; OTCQX: HEINY) hereby reports transaction details related to the second € 750 million tranche of its € 1.5 billion share buyback programme as communicated on 12 February 2026.

From 21 September 2026 up to and including 25 September 2026 a total of 164,417 shares were repurchased on exchange at an average price of € 71.27. During the same period, 164,949 shares were repurchased from Heineken Holding N.V.

Up to and including 25 September 2026, a total of 7,847,104 shares were repurchased under the second tranche of the share buyback programme for a total consideration of € 556,849,996 (including shares repurchased from Heineken Holding N.V.).

Heineken N.V. publishes on a weekly basis, every Monday, an overview of the progress of the share buyback programme on its website: https://www.theheinekencompany.com/investors/share-information/share-buyback-programme

Enquiries

Media			Investors
Christiaan Prins			Tristan van Strien
Director of Global Communication			Global Director of Investor Relations
Marlie Paauw			Lennart Scholtus / Isabelle van Rongen
Global Media Lead			Investor Relations Manager / Investor Relations Manager
E-mail: pressoffice@heineken.com			E-mail: investors@heineken.com
Tel: +31-20-5239355			Tel: +31-20-5239590

Regulatory information
This press release is issued in connection with the disclosure and reporting obligations as set out in Article 5(1)(b) Regulation (EU) 596/2014 and Article 2(2) of the Commission Delegated Regulation (EU) 2016/1052 that contains technical standards for buyback programs.

Editorial information:
HEINEKEN is the world’s pioneering beer company. It is the leading developer and marketer of premium and non-alcoholic beer and cider brands. Led by the Heineken® brand, the Group has a portfolio of more than 340 international, regional, local and specialty beers and ciders. With HEINEKEN’s over 85,000 employees, we brew the joy of true togetherness to inspire a better world. Our dream is to shape the future of beer and beyond to win the hearts of consumers. We are committed to innovation, long-term brand investment, disciplined sales execution and focused cost management. Through “Brew a Better World”, sustainability is embedded in the business. HEINEKEN has a well-balanced geographic footprint with leadership positions in both developed and developing markets. We operate breweries, malteries, cider plants and other production facilities in more than 70 countries. Most recent information is available on our Company’s website and follow us on LinkedIn and Instagram.

Attachment

• PR_SBB 2025_Weekly update_28-Sep-2026

Partnership Expands Flyte’s Growing Presence Across Entertainment, Fashion, Hospitality, Sports and Premium Destination Travel

2026 Flyte Breakthrough Awards will Honor Anthony Ippolito, Star of Amazon MGM Studios’ “I Play Rocky,” Rosalind Eleazar of Chris Rock’s “Misty Green,” and A24’s Jordan Firstman

Flyte Brand to be Prominent Throughout this Prestigious Eleven-Day Festival Bringing Together Leading Actors, Filmmakers, Executives and Audiences from Around the World

FORT MILL, S.C., Sept. 28, 2026 (GLOBE NEWSWIRE) — Flyte, a subsidiary of Catheter Precision, Inc. (NYSE American: VTAK) (“VTAK” or the “Company”), today announced it has established a partnership with the Hamptons International Film Festival (“HIFF”), in which Flyte has been named the ‘Official Air Travel Partner’ of the 34th annual HIFF taking place October 2 through October 12, 2026.

As Official Air Travel Partner, Flyte will have a prominent presence throughout the eleven-day festival, which brings together leading filmmakers, actors, artists, executives, and audiences from around the world for screenings, conversations, and events across the East End.

As a Lead Sponsor of the festival, Flyte’s presence extends across several of HIFF’s marquee programs. Flyte is also a sponsor of World Cinema Narrative, the Festival’s largest narrative section, featuring a wide-ranging slate of international films including Coward, Minotaur, Tender Loving Care and many more.

Additionally, Flyte will sponsor the Festival’s 2026 Breakthrough Honors, continuing a longstanding program with a history of recognizing emerging talent that has gone on to become some of the most prominent names in film and entertainment. The 2026 Flyte Breakthrough Award recipients include:

• Anthony Ippolito, who will receive a Flyte Breakthrough Performer Award in connection with I Play Rocky, the festival’s Opening Night film. Ippolito portrays Sylvester Stallone in the upcoming Amazon MGM Studios film.
• Rosalind Eleazar, who will receive a Flyte Breakthrough Performer Award for her performance in Misty Green, written and directed by Chris Rock.
• Jordan Firstman, who will receive the Flyte Breakthrough Director Award for Club Kid, an A24 release that Firstman wrote, directed and stars in.

The Festival’s Breakthrough program has previously recognized talent including Emma Stone, Mahershala Ali, Jessica Chastain, Lupita Nyong’o, Adam Driver, Brie Larson, Timothée Chalamet, Michael B. Jordan, Oscar Isaac and Emily Blunt.

“The Hamptons International Film Festival has become an important part of the cultural fabric of the East End, and we are proud to participate as its Official Air Travel Partner,” said Marc Sellouk, Founder of Flyte. “Flyte has developed a meaningful presence in the Hamptons, and this partnership feels like a natural extension of that. We are especially proud to lend the Flyte name to the Breakthrough Awards and recognize Anthony, Rosalind and Jordan alongside a program with an extraordinary history of talent.”

A Natural Connection to the Hamptons

As a natural showcase for the advantages of regional private aviation, the Hamptons have become an important market for Flyte.

Flyte operates a standardized fleet of Cirrus Vision Jets designed for short-haul private travel. Through its technology-enabled platform, customers can access private aviation through a streamlined digital experience, bringing greater simplicity and transparency to a travel category that historically had been complex to navigate.

For travel between the New York metro area and the East End, that combination is particularly relevant. What can otherwise require hours by car becomes a far more efficient journey by air, enabling travelers to spend more time at their destination and less time getting there. Furthermore, many of the smaller airports serviced by Flyte, which lack scheduled commercial air service, have far less surrounding traffic, easy ride-share access and more convenient parking than larger airports. The result is a unique expression of private aviation: not simply a solution for long-distance travel, but an increasingly seamless way to move between the places that matter.

“The most interesting part of regional private aviation is how naturally it can fit into someone’s life when the experience is simple,” Mr. Sellouk continued. “The aircraft, technology, booking platform and the customer-facing experience all must work together seamlessly. That is what we have built at Flyte, and the Hamptons exemplify this newly available and surprisingly affordable premium experience.”

A Growing Presence Across Culture and Travel

Whether traveling to the Hamptons for the film festival, New York for fashion week, a golf destination for the weekend, or The Bahamas for a resort stay, Flyte has built a private aviation platform designed around the way its customers actually travel.

The Company’s combination of a standardized aircraft fleet, technology-enabled booking experience and expanding network makes regional private aviation considerably more seamless while preserving the service, privacy and luxury experience expected from private travel.

About HamptonsFilm

HamptonsFilm, home of the Hamptons International Film Festival, was founded in 1992 to celebrate the art of film and introduce audiences to a diverse spectrum of international films and filmmakers. The organization presents the annual Hamptons International Film Festival along with year-round programming supporting filmmakers, artists and film culture.

About Flyte

Flyte is a technology-enabled private aviation company operating a growing fleet of Cirrus Vision Jets and providing efficient private air travel throughout the United States and select international markets. Through its direct-to-consumer booking platform, standardized pricing on select routes, strategic partnerships, and FAA-certified Part 135 operating subsidiary Ponderosa Air, LLC, Flyte is delivering a faster, safer, and more convenient private aviation experience.

For more information, visit www.flyflyte.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements regarding expected future growth, demand, strategic partnerships, market expansion, brand awareness, aircraft utilization and Flyte’s future operations, are forward-looking statements and involve risks and uncertainties that could cause actual results to differ materially. Readers are encouraged to review the Company’s filings with the Securities and Exchange Commission, including its Forms 10-K and 10-Q, for a discussion of these risks.

Contact
IR@CatheterPrecision.com

Transaction Includes Sale-Leaseback of 17 Aircraft with Strategic Capital’s Second Investment Vehicle and Acquisition of 10 Off-Lease Aircraft to Support FTAI’s Aerospace Products Business

NEW YORK, Sept. 28, 2026 (GLOBE NEWSWIRE) — FTAI Aviation Ltd. (NASDAQ: FTAI; the “Company” or “FTAI”) today announced the acquisition of 27 Boeing 737-700 aircraft from WestJet. The acquisition marks one of FTAI’s largest aircraft transactions to date.

Under the transaction, FTAI’s 2026 SPV, the second investment vehicle of the Company’s Strategic Capital business, acquired 17 Boeing 737-700 aircraft on lease to WestJet in a sale-leaseback, and FTAI acquired 10 off-lease Boeing 737-700 aircraft to support its Aerospace Products business.

The 2026 SPV was formed to acquire on-lease, mid-life 737NG and A320ceo aircraft and follows the 2025 SPV, FTAI’s inaugural Strategic Capital vehicle, which raised $2.0 billion of equity commitments and has committed approximately $6.0 billion of total capital across more than 300 aircraft. This transaction highlights FTAI’s position as a differentiated buyer of mid-life narrowbody aircraft, combining aircraft ownership through its Strategic Capital vehicles with its leading engine maintenance capabilities.

The 10 off-lease aircraft will support FTAI’s Aerospace Products business by expanding the Company’s supply of CFM56-7B engines and modules available to its Maintenance, Repair and Exchange customers.

“We are pleased to expand our relationship with WestJet through this transaction,” said David Moreno, President at FTAI. “It demonstrates how our Strategic Capital and Aerospace Products businesses work together to offer airlines comprehensive fleet solutions, from sale-leaseback capital for in-service aircraft to a flexible exit for aircraft transitioning out of the fleet. For Aerospace Products, the retiring aircraft will add CFM56-7B engines and modules to the exchange pool to support our customers’ maintenance requirements.”

“This 27-aircraft transaction is a strategic milestone that officially marks the start of our retirement of our 737-700 fleet. We’re pleased to partner with FTAI Aviation Ltd. to make this happen, and we look forward to building on this relationship for future opportunities,” said Mike Scott, WestJet Group Executive Vice-President and Chief Financial Officer.

McGuireWoods served as counsel to FTAI and BD&P served as counsel to WestJet in connection with the transaction.

Cautionary Note Regarding Forward-Looking Statements

Certain statements in this press release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, the expected benefits of the transaction, the 2026 SPV’s acquisition plans and deployment of capital, the Company’s ability to perform engine maintenance for the leased aircraft, and the expected contribution of the acquired aircraft and engines to the Company’s Aerospace Products business. These statements are based on management’s current expectations and beliefs and are subject to a number of trends and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, many of which are beyond the Company’s control. The Company can give no assurance that its expectations will be attained and such differences may be material. Accordingly, you should not place undue reliance on any forward-looking statements contained in this press release. For a discussion of some of the risks and important factors that could affect such forward-looking statements, see the sections entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, which are available on the Company’s website (www.ftaiaviation.com). In addition, new risks and uncertainties emerge from time to time, and it is not possible for the Company to predict or assess the impact of every factor that may cause its actual results to differ from those contained in any forward-looking statements. Such forward-looking statements speak only as of the date of this press release. The Company expressly disclaims any obligation to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with regard thereto or change in events, conditions, or circumstances on which any statement is based. This release shall not constitute an offer to sell or the solicitation of an offer to buy any securities. Nothing on the Company’s website is included or incorporated by reference herein.

About FTAI

FTAI combines advanced turbine technology and asset ownership to power the world’s most essential markets. Additional information is available at https://www.ftaiaviation.com.

For further information, please contact:

FTAI:
Charlie Arestia
Investor Relations
(646) 276-4418
ir@ftaiaviation.com

Media:
Tim Lynch / Kelly Sullivan
Joele Frank, Wilkinson Brimmer Katcher
(212) 355-4449

MN-001 showed statistically significant increases in HDL-C and HDL-P and significant early reduction in triglyceride, a reduction in body weight and a numerical improvement in liver fat

LA JOLLA, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the topline results from MN-001-NATG-202, a Phase 2 clinical trial evaluating MN-001 (tipelukast) for the treatment of hypertriglyceridemia and nonalcoholic fatty liver disease (NAFLD) associated with type 2 diabetes mellitus (T2DM). In the MN-001 group, reductions in serum triglycerides (TG), increases in serum high-density lipoprotein cholesterol (HDL-C) and HDL particle concentration (HDL-P), and a numerical trend toward improvement in liver fat and body weight were observed. MN-001 demonstrated a generally favorable safety and tolerability profile.

Study Overview

MN-001-NATG-202 was a randomized, double-blind, placebo-controlled study designed to evaluate the efficacy, safety, and tolerability of MN-001 in 40 patients with NAFLD and hypertriglyceridemia associated with T2DM. The treatment period was 24 weeks.

Key Results

• Serum TG: At Week 24, mean serum TG decreased from baseline by 45.8 mg/dL (21.78%) in the MN-001 group and by 14.4 mg/dL (6.97%) in the placebo group. Thus, the mean decrease was 31.4 mg/dL greater with MN-001 than with placebo (p=0.113). At Week 4, mean serum TG decreased from baseline by 54.7 mg/dL (26.05%) in the MN-001 group and by 23.8 mg/dL (11.54%) in the placebo group. The mean decrease was 30.96 mg/dL greater with MN-001 than with placebo, and this difference was statistically significant (p=0.015).
• Liver fat: At Week 24, the mean controlled attenuation parameter (CAP) score measured by FibroScan® decreased from baseline by 14.1 dB/m (4.24%) in the MN-001 group and by 4.3 dB/m (1.27%) in the placebo group. Thus, the mean decrease was 9.7 dB/m greater with MN-001 than with placebo; however, this difference was not statistically significant (p=0.2438).
• HDL-C: At Week 24, mean HDL-C increased by 3.3 mg/dL (8.39%) in the MN-001 group but decreased by 2.4 mg/dL (6.23%) in the placebo group. The difference between the MN-001 and placebo groups was 5.7 mg/dL and was statistically significant (p=0.0048).
• HDL-P: At Week 24, mean HDL-P increased by 3.62 µmol/L (11.80%) in the MN-001 group but decreased by 0.9 µmol/L (3.00%) in the placebo group. The difference between the MN-001 and placebo groups was 4.52 µmol/L and was statistically significant (p=0.018).
• Body weight: At the end of the study, mean body weight decreased by 4.91 lb (2.28%) in the MN-001 group and by 0.55 lb (0.25%) in the placebo group. Thus, the mean decrease in body weight was 4.36 lb greater with MN-001 than with placebo (p=0.082).

Safety and Tolerability

MN-001 was generally safe and well tolerated. Treatment-related adverse events were mild to moderate in severity, and no drug related serious adverse events (SAEs) were reported in the study.

Clinical Significance of the Results

The study demonstrated a statistically significant reduction in serum TG at Week 4 with MN-001 than with placebo. At Week 24, the MN-001 group continued to show a numerical reduction from baseline value, although the difference between the MN-001 and placebo groups were not statistically significant. Statistically significant increases in HDL-C and HDL-P were also observed with MN-001 group while liver fat and body weight showed trends toward improvement. Collectively, these exploratory findings suggest that MN-001 may have beneficial effects across in several metabolic parameters including lipid metabolism, body weight, and liver fat.

The changes in TG, HDL-C, and HDL-P were also consistent with findings from preclinical in-vitro mechanism of action studies and previous MN-001-NATG-201 clinical trial. Together with the clinical findings, these results provide a basis for further evaluation of MN-001 in metabolic and cardiovascular diseases.

Next Steps

This was a proof of concept, exploratory study involving 40 patients. Preliminary review of the topline data indicates that efficacy should be evaluated in a larger study. We will continue detailed analyses of the study data and assess the next stage of clinical development, including the appropriate patient population, endpoints, and sample size.

About MN-001

MN-001 (tipelukast) is a novel, orally bioavailable, small-molecule compound thought to exert its effects through several mechanisms to produce anti-inflammatory and antifibrotic activity in preclinical models, including leukotriene (LT) receptor antagonism, inhibition of phosphodiesterase (PDE) (mainly 3 and 4), and inhibition of 5-lipoxygenase (5-LO). The 5-LO/LT pathway has been postulated as a pathogenic factor in fibrosis development, and MN-001’s inhibitory effect on 5-LO and the 5-LO/LT pathway is a novel approach to treating fibrosis. MN-001 has been shown to down-regulate expression of genes that promote fibrosis, including LOXL2, Collagen Type 1, and TIMP-1. MN-001 has also been shown to down-regulate expression of genes that promote inflammation, including CCR2 and MCP-1. It also inhibits triglyceride synthesis in hepatocytes by inhibiting arachidonic acid uptake. Recent research suggested that MN-002, the major metabolite of MN-001, significantly enhanced cholesterol efflux in macrophages by upregulating key transport proteins ABCA1 and ABCG1.

About Type 2 Diabetes Mellitus (T2DM), Dyslipidemia, and Nonalcoholic Fatty Liver Disease (NAFLD)

Type 2 diabetes mellitus (T2DM) is a metabolic disorder characterized by insulin resistance, which plays a central role in the development of dyslipidemia—abnormal levels of lipids in the blood.　Hypertriglyceridemia (elevated triglycerides) is commonly observed in individuals with T2DM. It results from increased hepatic lipid synthesis and impaired clearance of triglyceride-rich lipoproteins. Hypercholesterolemia, particularly elevated LDL cholesterol and reduced HDL cholesterol, is also frequently seen and contributes to a higher risk of atherosclerosis. Dyslipidemia not only worsens glycemic control but also increases the risk of cardiovascular complications and liver-related conditions such as nonalcoholic fatty liver disease (NAFLD). NAFLD is considered a hepatic complication of insulin resistance and is frequently associated with T2DM and dyslipidemia.

About MediciNova

MediciNova, Inc. is a clinical-stage biopharmaceutical company developing a broad late-stage pipeline of novel small-molecule therapies for inflammatory, fibrotic, and neurodegenerative diseases. Based on two compounds, MN-166 (ibudilast) and MN-001 (tipelukast), each with multiple mechanisms of action and strong safety profiles, MediciNova has 11 programs in clinical development. MediciNova’s lead asset, MN-166 (ibudilast), is currently in Phase 3 for amyotrophic lateral sclerosis (ALS) and degenerative cervical myelopathy (DCM) and is Phase 3-ready for progressive multiple sclerosis (MS). MN-166 (ibudilast) is also being evaluated in Phase 2 trials in Long COVID and substance dependence. MN-001 (tipelukast) was evaluated in a Phase 2 trial in idiopathic pulmonary fibrosis (IPF), and a second Phase 2 trial in nonalcoholic fatty liver disease (NAFLD) is ongoing. MediciNova has a strong track record of securing investigator-sponsored clinical trials funded through government grants.

Forward-Looking Statements

Statements in this press release that are not historical in nature constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding the future development and efficacy of MN-166 and MN-001. These forward-looking statements may be preceded by, followed by, or otherwise include the words “believes,” “expects,” “anticipates,” “intends,” “estimates,” “projects,” “can,” “could,” “may,” “will,” “would,” “considering,” “planning” or similar expressions. These forward-looking statements involve a number of risks and uncertainties that may cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Factors that may cause actual results or events to differ materially from those expressed or implied by these forward-looking statements include, but are not limited to, risks of obtaining future partner or grant funding for development of MN-166 and MN-001, and risks of raising sufficient capital when needed to fund MediciNova’s operations and contribution to clinical development, risks and uncertainties inherent in clinical trials, including the potential cost, expected timing and risks associated with clinical trials designed to meet FDA guidance and the viability of further development considering these factors, product development and commercialization risks, the uncertainty of whether the results of clinical trials will be predictive of results in later stages of product development, the risk of delays or failure to obtain or maintain regulatory approval, risks associated with the reliance on third parties to sponsor and fund clinical trials, risks regarding intellectual property rights in product candidates and the ability to defend and enforce such intellectual property rights, the risk of failure of the third parties upon whom MediciNova relies to conduct its clinical trials and manufacture its product candidates to perform as expected, the risk of increased cost and delays due to delays in the commencement, enrollment, completion or analysis of clinical trials or significant issues regarding the adequacy of clinical trial designs or the execution of clinical trials, and the timing of expected filings with the regulatory authorities, MediciNova’s collaborations with third parties, the availability of funds to complete product development plans and MediciNova’s ability to obtain third party funding for programs and raise sufficient capital when needed, and the other risks and uncertainties described in MediciNova’s filings with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2025 and its subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Undue reliance should not be placed on these forward-looking statements, which speak only as of the date hereof. MediciNova disclaims any intent or obligation to revise or update these forward-looking statements.

INVESTOR CONTACT:

David H. Crean, Ph.D.
Chief Business Officer
MediciNova, Inc
info@medicinova.com